LEGN · Legend Biotech Corporation

The thesis

Legend Biotech's recovery case rests on CARVYKTI sales that reached about $710 million in the third quarter of 2026, and on whether the second quarter's first adjusted profit repeats. The shares closed at $21.56 on 27 October 2026, up from $19.04 on 14 October 2026. Legend's third-quarter report and 8:00 a.m. ET call on 10 November 2026 settle whether the profit held.

Legend announced the preliminary sales figure on 13 October 2026 under its collaboration with Johnson & Johnson's Janssen unit. The 27 October 2026 close sits 40.6% below the 52-week high of $36.28 and 13.2% above the close three months earlier. The 14-day relative strength index (RSI, a 0-to-100 gauge of recent buying pressure) is 64.4.

The narrative is maturing: the profit story is well known, and the shares have recovered part of the October drop without any new financial result since the 13 October 2026 sales release. The rebound followed a pipeline item, not a profit figure. On 15 October 2026 Legend said the FDA cleared the investigational new drug application for LB2501, an in vivo CD19/CD20 CAR-T therapy, for a US Phase 1/2 trial. Conviction stays low because the profit repeat is not yet reported and analyst targets were cut three weeks ago.

Bullish and bearish views on Legend Biotech Corporation

The bull case on Legend Biotech Corporation (LEGN), in brief: Sales cleared the prior quarter. The bear case: The profit repeat is unconfirmed.

Bull case

• Sales cleared the prior quarter. Legend reported preliminary third-quarter CARVYKTI net trade sales of about $710 million on 13 October 2026, against about $657 million in the second quarter, which was up 50% from a year earlier. The figure is unaudited and partner-provided.
• Profit has a reported anchor. Second-quarter revenue was $387.5 million and adjusted net income was $63.1 million, Legend's first adjusted profit (results release, 11 August 2026). The company said it expects to stay adjusted-profitable in the second half of 2026.

• Durability data are strong. In CARTITUDE-2 Cohort A, 10 of 20 patients (50%) were alive and progression-free at five years without maintenance therapy; five-year overall survival was 69.2% (Legend release, 25 September 2026).
• A next-generation program cleared the FDA. Legend announced on 15 October 2026 that the FDA cleared the LB2501 application, which Legend describes as the first dual-targeting in vivo CAR-T therapy to receive such clearance. Early clinical reports described expansion of the CAR-T cells in 6 of 6 patients at the higher dose; the cohort is too small to support a conclusion about efficacy.
• Analysts remain far above the price. RBC Capital's target is $56 (8 October 2026), Barclays' is $68 (13 October 2026) and HC Wainwright's is $65 (30 September 2026).

Bear case

• The profit repeat is unconfirmed. The only profitable quarter to date is the second quarter's $63.1 million adjusted net income. Sales growth does not by itself show margin or expense results; the 10 November 2026 report does.
• Analysts lowered targets in October. JPMorgan maintained Neutral and cut its target to $33 on 9 October 2026. RBC cut to $56 and Barclays to $68. MarketBeat's 26 September 2026 list had TD Cowen at $24, so published targets span a wide range.
• Share supply keeps growing. The 17 June 2026 offering priced at $29.35 per American depositary share (ADS), well above the current close. Shareholders approved a 19,100,000-ordinary-share increase to the restricted share plan on 24 September 2026.
• Competition arrives in December. The FDA action date for Gilead and Arcellx's anito-cel in relapsed or refractory multiple myeloma is 23 December 2026. A cleaner neurotoxicity label than CARVYKTI's would sharpen the competitive picture.
• Leadership is new. Ingrid Zhang became chief executive on 15 September 2026, with Alan Bash returning as President, CARVYKTI. No quarterly report has yet been issued under her.

Price setup

The shares closed at $21.56 on 27 October 2026 (adjusted daily closes). That is above the 14 October 2026 close of $19.04 and the 1 October 2026 close of $19.32, and well above the September low of $17.61 set on 18 September 2026.

The price remains 40.6% below the 52-week high of $36.28. MarketBeat reported a 50-day moving average of $20.25 and a 200-day moving average of $23.55 on 26 September 2026. The latest close is above the 50-day figure and below the 200-day figure as of that date; current averages were not available.

Crowding evidence is limited to an imminent earnings date, 14 calendar days after the latest close, and insider selling by the chief financial officer on 21 September 2026. Share issuance in June and a larger equity plan approved in September add to supply. Heavy retail attention is not documented.

Catalysts, next 30 days

• 10 November 2026, 8:00 a.m. ET: Legend's third-quarter 2026 report and investor call, announced by the company on 27 October 2026. It shows whether adjusted net income stayed positive after $63.1 million in the second quarter, and whether gross margin landed in the guided range.
• 23 December 2026 (outside the 30 days, but the case turns on it): FDA action date for anito-cel in relapsed or refractory multiple myeloma. It sets the competitive structure for later-line BCMA CAR-T therapy and CARVYKTI's share outlook.

What would change the view

The case breaks if Legend reports an adjusted net loss for the third quarter on 10 November 2026, after the $63.1 million adjusted profit in the second quarter. It also breaks if the final CARVYKTI sales figure falls materially below the preliminary $710 million.

A weekly close below $17.61, the 18 September 2026 close and the September low, would end the recovery case on price. A cleaner neurotoxicity label for anito-cel on or before 23 December 2026 would weaken the competitive part of the case. A confirmed second adjusted profit, with further target cuts absent, would strengthen it.

What it trades with

CARVYKTI is shared roughly 50/50 with Johnson & Johnson, so J&J's reported CARVYKTI sales set Legend's collaboration economics. Gilead and Arcellx are the nearest direct competitors through anito-cel. Legend's China-based research means US-China biotech policy headlines can move the ADSs. The shares also trade with the wider cell-therapy and oncology group, where financing conditions and clinical readouts move prices together.